About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 574 record(s)
Req # A-2023-001214
Correspondence relating to any abbreviated new drug submission (ANDS) filed since July 1, 2023 where the medicinal ingredient is liraglutide alone and the indication includes chronic weight management.Organization: Health Canada
January 2024
Req # A-2023-001223
Complete copy of documents in your possession relating to the subject company. NEQ : 1167802090.Organization: Health Canada
January 2024
Req # A-2023-001293
The implementation of the 9-8-8 suicide crisis helpline since its launch on November 30, 2023, up until January 13, 2024. Obtain copies of all data and statistics related to this initiative, including the daily, weekly and monthly volume of calls received, broken down by city, province and gender and an estimate of the number of lives saved since its creation.Organization: Health Canada
January 2024
Req # A-2023-001297
The number of excess deaths caused by cardiovascular problems since January 1, 2020.Organization: Health Canada
January 2024
Nothing to report this month
Organization: Canada Hibernia Holding Corporation
Req # A-2017-000565
All reports or records in the custody or control of Health Canada, in any format relating to communications within Health Canada or between Health Canada and its external consultants or experts regarding the potential connection between food and beverage marketing and childhood obesity. Date Range: January 1, 2015 to July 19, 2017.Organization: Health Canada
January 2023
Req # A-2018-000773
Between January 1, 2014 to August 30, 2018: Any submissions or other correspondence received by Health Canada regarding pharmaceuticals manufacturer coupon card programs and any response issued by Health Canada to such submissions or correspondence.Organization: Health Canada
January 2023
Req # A-2018-001470
All safety reviews of Rasilez (aliskiren) or c since the products were first approved in Canada to January 18, 2019.Organization: Health Canada
January 2023
Req # A-2019-000536
All documents regarding the approval of Crest Gum Detoxify from the Licensed Natural Health Products Database.Organization: Health Canada
January 2023
Req # A-2020-000178
The patient consent forms, clinical trial protocols, and investigator brochures/information (including amendments to any of the foregoing) for the following clinical trials included in: 1. Title: Multicenter Study of the Safety and Efficacy of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis. 2. Title: Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy. 3. Title: Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis. 4. Title: A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn’s Disease. 5. Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn’s Disease, Open Label Extension.Organization: Health Canada
January 2023